Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RVMD

RVMD - REVOLUTION Medicines Inc Stock Price, Fair Value and News

$97.34-2.48 (-2.48%)
Market Closed

11/100

RVMD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

RVMD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$94.1

Target 3M

$105.87

Target 6M

$99.99

RVMD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RVMD Price Action

Last 7 days

-17.2%

Last 30 days

20.9%

Last 90 days

65.4%

Trailing 12 Months

137.9%

RVMD RSI Chart

RVMD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RVMD Valuation

Market Cap

18.8B

Price/Earnings (Trailing)

-19.58

Price/Sales (Trailing)

990.64

EV/EBITDA

-19.49

Price/Free Cashflow

-24.22

RVMD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$94.1

Target 3M

$105.87

Target 6M

$99.99

RVMD Fundamentals

RVMD Revenue

Revenue (TTM)

11.6M

RVMD Earnings

Earnings (TTM)

-961.0M

Earnings Growth (Yr)

-95.28%

Earnings Growth (Qtr)

-23.17%

RVMD Profitability

EBT Margin

-8305.10%

Return on Equity

-60.18%

Return on Assets

-42.67%

Free Cashflow Yield

-4.13%

RVMD Investor Care

Shares Dilution (1Y)

14.92%

Diluted EPS (TTM)

-5.18

RVMD Alerts

  • 3 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202334.8M29.5M26.2M11.6M
202226.8M27.3M29.5M35.4M
202141.6M40.2M28.7M29.4M
202048.4M46.2M46.3M43.0M
201927.6M35.1M42.6M50.0M
201800020.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About REVOLUTION Medicines Inc

RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
 CEO
 WEBSITErevmed.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES292

REVOLUTION Medicines Inc Frequently Asked Questions

RVMD is the stock ticker symbol of REVOLUTION Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of REVOLUTION Medicines Inc is 18.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RVMD's fair value in chart for subscribers.

The fair value guage provides a quick view whether RVMD is over valued or under valued. Whether REVOLUTION Medicines Inc is cheap or expensive depends on the assumptions which impact REVOLUTION Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVMD.

As of Wed Jan 28 2026, RVMD's PE ratio (Price to Earnings) is -19.58 and Price to Sales (PS) ratio is 990.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RVMD PE ratio will change depending on the future growth rate expectations of investors.